First-in-human safety, tolerability, pharmacokinetics and pilot food-effect study of the candidate antimalarial compound MMV367

被引：0

作者：

Kuemmerle, Andrea ^{[1
]}

Singh, Nand ^{[2
]}

Gossen, Denis ^{[3
]}

Janin, Annick ^{[4
]}

Sharma, Raman ^{[5
]}

Cahn, Anthony ^{[6
]}

Gibson, Rachel A. ^{[6
]}

Menakuru, Somasekhara R. ^{[2
]}

Lambourne, Erin ^{[2
]}

Dove, Tom ^{[2
]}

Gamo, Francisco-Javier ^{[7
]}

Sanz, Laura ^{[7
]}

Bestgen, Benoit ^{[1
]}

Chalon, Stephan ^{[1
]}

机构：

[1] MMV Med Malaria Venture, 20 Route de Pre Bois 1215, CH-1215 Geneva 15, Switzerland

[2] Quotient Sci, Nottingham, England

[3] Mangareva SRL, Kraainem, Belgium

[4] AKJ Consulting, Divonne, France

[5] GSK, Clin Pharmacol & Simulat R&D, Stevenage, England

[6] GSK, Global Hlth Med R&D, Stevenage, England

[7] GSK, Global Hlth Med R&D, Tres Cantos, Spain

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2025年

基金：

比尔及梅琳达.盖茨基金会;

关键词：

first-in-human; GSK3772701; malaria; MMV367; pharmacokinetics; safety; tolerability;

D O I：

10.1002/bcp.70000

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

AimTo evaluate the safety, tolerability and pharmacokinetics in healthy participants of orally administered MMV367 (GSK3772701), a novel antimalarial interfering with Plasmodium falciparum acyl coenzyme A synthetase 10/11 function.MethodsThis first-in-human study enrolled 47 healthy male and female participants. Part 1 was a randomised, double-blind, placebo-controlled study in which four sequential fasted cohorts received MMV367 single ascending doses (100, 300, 750 and 1500 mg) or placebo (six active, two placebo per cohort). Part 2 was a randomised, open-label crossover (fed-fasted) pilot food-effect study of MMV367 440 mg (n = 8). In Part 3 MMV367 400 mg was administered once daily for 3 days in a single cohort (six active, two placebo).ResultsTreatment-emergent adverse events (TEAEs) occurred in 36.8% (14/38) of participants receiving MMV367 vs 44.4% (4/9) with placebo. There were two MMV367-related TEAEs, and no serious or severe TEAEs or clinically relevant changes in electrocardiograms, vital signs or laboratory tests. In Part 1 (fasted), maximum plasma concentrations occurred between 2.0 and 5.0 h post dose, with a geometric mean half-life of 16.5-18.4 h. Approximate dose proportionality was demonstrated across the dose range (100-1500 mg). In Part 2, MMV367 relative bioavailability (fed vs fasted) was 161.4% (90% confidence interval 148.3, 175.6) for maximum observed concentration (Cmax), 130.4% (122.2, 139.1) for the area under the curve (AUC) until the last measurable concentration and 132.9% (124.1, 142.3) for AUC extrapolated to infinity. In Part 3, geometric mean day 1:3 exposure ratios (geometric co-efficient of variability) were 1.9 (4.9%) for Cmax and 2.1 (7.7%) for the AUC for the defined interval between doses after once-daily dosing for 3 days.ConclusionsMMV367 demonstrated acceptable safety, tolerability and pharmacokinetic profiles supporting further development as an antimalarial drug.

引用

页数：13

共 22 条

[1] World malaria report
[2] Gallego-Delgado J., Pathology of severe malaria, Pathogens, 12, (2023)
[3] Bopp S., Pasaje C.F.A., Summers R.L., Et al., Potent acyl-CoA synthetase 10 inhibitors kill Plasmodium falciparum by disrupting triglyceride formation, Nat Commun, 14, 1, (2023)
[4] Alexander S.P., Fabbro D., Kelly E., Et al., The concise guide to pharmacology 2021/22: enzymes, Br J Pharmacol, 178, pp. S313-S411, (2021)
[5] Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, (2005)
[6] Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products – Scientific guideline, (2017)
[7] Guidance for industry: food-effect bioavailability and fed bioequivalence studies, (2002)
[8] Bowman C.J., Becourt-Lhote N., Boulifard V., Et al., Science-based approach to harmonize contraception recommendations in clinical trials and pharmaceutical labels, Clin Pharmacol Ther, 113, 2, pp. 226-245, (2023)
[9] Zann V., McDermott J., Jacobs J.W., Et al., Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate, Drug Des Devel Ther, 11, pp. 2663-2673, (2017)
[10] Harding S.D., Armstrong J.F., Faccenda E., Et al., The IUPHAR/BPS guide to PHARMACOLOGY in 2024, Nucleic Acids Res, 52, D1, pp. D1438-D1449, (2024)

← 1 2 3 →